Solid Biosciences Inc. (SLDB) is a life science company that is dedicated to solving Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. It is one of several types of muscular dystrophy and primarily affects boys. Solid Biosciences aims towards understanding the disease and finding meaningful therapies that can help the patients.
Founded in 2013, Solid Biosciences has its headquarters in Cambridge, Massachusetts. The company has a multidisciplinary approach and utilizes a combination of therapeutic platforms to address the complex nature of the disease. Its primary focus is on correcting the genetic mutation that causes DMD and protecting and restoring the function of the dystrophin protein.
SLDB’s portfolio of different treatments includes gene therapy, small molecule, and protein replacement therapy. Its lead candidate, SGT-001, is a gene transfer under investigation that aims to address the root cause of DMD by delivering a functional copy of the dystrophin gene to muscle cells, thereby restoring the expression of the protein.
However, developing treatments for such a severe and rare disease is not without its challenges. The company faced potential setbacks when its clinical trial for SGT-001 was halted by FDA due to safety concerns. The hurdles didn't hamper the spirit of the team, however, and they continue to work hard to bring innovative solutions for the management and potential cure of DMD.
Tangible demonstrations of the company's commitment include its Solid GT division dedicated to advancing new gene therapies and small molecules, and The Duchenne Registry, a patient-reported outcome registry that helps researchers understand the progression of DMD and the impact of treatments.
What sets Solid Biosciences apart is its commitment not just to science, but also to the people living with DMD. The company's name itself is a nod to this tradition, with “Solid” being inspired by the moniker of the company’s co-founder's son, who is diagnosed with DMD.
By leveraging cutting-edge science, focusing on the highest standards of care, and maintaining a deep sense of compassion, Solid Biosciences Inc. symbolizes hope for thousands of families affected by Duchenne muscular dystrophy worldwide. As we look into the future, the ongoing dedication and transformative research of Solid Biosciences is making the prospect of better treatments, improved quality of life and perhaps, one day, a cure for DMD an achievable reality.